Sunshine Biopharma (NASDAQ:SBFM) Trading Down 3.8% – Time to Sell?

Shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) were down 3.8% during trading on Monday . The stock traded as low as $2.03 and last traded at $2.05. 72,764 shares traded hands during trading, a decline of 93% from the average session volume of 999,015 shares. The stock had previously closed at $2.13.

Analyst Upgrades and Downgrades

SBFM has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sunshine Biopharma in a research note on Tuesday, April 21st. Zacks Research raised shares of Sunshine Biopharma to a “hold” rating in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $70.00.

Sunshine Biopharma Trading Down 3.8%

The firm has a market capitalization of $1.02 million, a P/E ratio of -0.16 and a beta of 1.13. The business has a 50-day moving average of $6.11 and a 200 day moving average of $10.01.

Sunshine Biopharma (NASDAQ:SBFM) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($2.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.90). Sunshine Biopharma had a negative return on equity of 27.75% and a negative net margin of 18.45%.The firm had revenue of $8.09 million during the quarter, compared to the consensus estimate of $9.20 million. As a group, research analysts forecast that Sunshine Biopharma, Inc. will post -6.3 EPS for the current year.

Hedge Funds Weigh In On Sunshine Biopharma

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of Sunshine Biopharma in the 4th quarter worth $29,000. Citadel Advisors LLC increased its stake in Sunshine Biopharma by 23.1% during the 3rd quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock valued at $116,000 after purchasing an additional 14,656 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in Sunshine Biopharma during the third quarter worth $32,000. 41.98% of the stock is owned by institutional investors and hedge funds.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.